# A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adult Participants for the Treatment of Nasolabial Folds

> **NCT06018987** · PHASE2,PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 61 (actual)

## Conditions studied

- Nasolabial Folds

## Interventions

- **OTHER:** No-Treatment Control
- **DEVICE:** HAC 20L

## Key facts

- **NCT ID:** NCT06018987
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-05
- **Primary completion:** 2025-02-03
- **Final completion:** 2025-02-03
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06018987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06018987, "A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adult Participants for the Treatment of Nasolabial Folds". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06018987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*